Honest answers to the questions people actually ask.

There's no honest one-word answer, because "peptides" isn't one thing. The word covers everything from a rigorously trialled prescription medicine like insulin to an unverified vial bought from an online vendor. A licensed peptide medicine has known, documented risks from large human trials. An unregulated research peptide often has unknown risks, little human data, and no guarantee the product even contains what the label says. Those aren't the same situation.

The book devotes its whole framework to this: how to tell which world a given peptide belongs to, and what question to ask instead of "is it safe?"

BPC-157 is the most-discussed research peptide, and the honest position sits between the enthusiasts and the sceptics. The preclinical animal data is genuinely interesting — but a 2025 review in the American Journal of Sports Medicine screened 544 published articles and found only one was a clinical study in humans. So the honest answer is: promising biology, real anecdotes, and almost no rigorous human evidence to confirm it works in people.

The book breaks down exactly what the research does and doesn't show — and why the marketing has run so far ahead of the evidence.

This is one of the most-asked concerns, and it's a fair one to raise. The worry comes from how BPC-157 is thought to work — by promoting the growth of new blood vessels (angiogenesis) and supporting cell growth, which are also processes that tumours can exploit. To be clear: there is currently no evidence that BPC-157 causes cancer in humans. But because the long-term human safety data simply doesn't exist, "we don't know" is the honest answer — not "it's fine."

The book explains the mechanism plainly, separates the theoretical concern from evidence, and puts it in the wider context of what long-term data we actually have.

This has become one of the most urgent questions in the whole field, and for good reason. Regulators including the FDA, the UK's MHRA, Australia's TGA and the WHO have all issued warnings about counterfeit semaglutide. Testing has found fake products containing the wrong drug, the wrong dose, or no active ingredient at all — in some cases insulin instead of semaglutide, which has hospitalised people. The single most reliable protection is obtaining it by prescription through a licensed pharmacy, not an online seller.

The book's chapter on counterfeits goes deep here — including how the supply chain actually works and why so much of what's sold online isn't what it claims to be.

Every few months a new name gets hyped as the next big thing. Some, like retatrutide, are genuine pharmaceutical compounds with striking clinical-trial data — but not yet approved, meaning anything sold under the name outside a trial isn't the regulated product. Others, like TB-500, are marketed on the back of research that was actually done on a different molecule entirely. The pattern repeats: real science and marketing spin get blended until you can't tell them apart.

The book covers each of these compound-by-compound, so you can see where the real evidence ends and the hype begins.